Table 2: Treatment characteristics overall and by heart
failure subtypes.
|
Treatment |
Overall N=251 |
HFpEF n=47 |
HFmrEF (n= 44) |
HFrEF (n= 160) |
P |
|
Diuretics
(%) |
247
(98.4) |
45
(95.7) |
44
(100) |
158 (98.8) |
0.23 |
|
ACE I / ARB drugs |
225 (89.6) |
42 (89.4) |
40 (90.9) |
144 (89.4) |
0.95 |
|
BetaBlockers (%) |
132 (52.6) |
18(38.3)* |
26 (59.1) |
88 (55) |
0.08 |
|
Digitalis (Digoxin) (%) |
124 (49.4) |
12 (25.5)* |
18 (40) |
94 (58.8) § |
< 0.001 |
|
Nitrates (%) |
139 (55.4) |
35 (74.5)* |
26 (59.4) |
78 (48) § |
0.007 |
|
Aldosterone antagonist(%) |
176 (70.1) |
25 (53.2* |
32 (72.2) |
119 (74.4) |
0.019 |
|
Length
of stay in hospital |
8.5
± 5.2 |
7.1
± 2.9 |
7.8
± 4.6 |
8.4
± 5.8 |
0.31 |
HFmrEF,
heart failure with mid-range ejection fraction; HFpEF, heart failure with
preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker.
*p
<0.05 for HFpEF vs. HFrEF
†p
<0.05 for HFmrEF vs. HFpEF.
§p
<0.05 for HFmrEF vs. HFrEF